150 related articles for article (PubMed ID: 25734915)
1. A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.
Rueda A; García-Sanz R; Pastor M; Salar A; Labrador J; Quero-Blanco C; Casanova M; Provencio M;
Acta Oncol; 2015 Jun; 54(6):933-8. PubMed ID: 25734915
[TBL] [Abstract][Full Text] [Related]
2. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S
Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584
[TBL] [Abstract][Full Text] [Related]
4. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
5. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
[TBL] [Abstract][Full Text] [Related]
7. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Tuscano JM; Dutia M; Chee K; Brunson A; Reed-Pease C; Abedi M; Welborn J; O'Donnell RT
Br J Haematol; 2014 May; 165(3):375-81. PubMed ID: 24606326
[TBL] [Abstract][Full Text] [Related]
9. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Suvannasankha A; Fausel C; Juliar BE; Yiannoutsos CT; Fisher WB; Ansari RH; Wood LL; Smith GG; Cripe LD; Abonour R
Oncologist; 2007 Jan; 12(1):99-106. PubMed ID: 17227904
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
11. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
Younes A; Sureda A; Ben-Yehuda D; Zinzani PL; Ong TC; Prince HM; Harrison SJ; Kirschbaum M; Johnston P; Gallagher J; Le Corre C; Shen A; Engert A
J Clin Oncol; 2012 Jun; 30(18):2197-203. PubMed ID: 22547596
[TBL] [Abstract][Full Text] [Related]
12. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Vose JM; Habermann TM; Czuczman MS; Zinzani PL; Reeder CB; Tuscano JM; Lossos IS; Li J; Pietronigro D; Witzig TE
Br J Haematol; 2013 Sep; 162(5):639-47. PubMed ID: 23834234
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Straus DJ; Hamlin PA; Matasar MJ; Lia Palomba M; Drullinsky PR; Zelenetz AD; Gerecitano JF; Noy A; Hamilton AM; Elstrom R; Wegner B; Wortman K; Cella D
Br J Haematol; 2015 Mar; 168(5):663-70. PubMed ID: 25316653
[TBL] [Abstract][Full Text] [Related]
17. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
18. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Tarella C; Cuttica A; Vitolo U; Liberati M; Di Nicola M; Cortelazzo S; Rosato R; Rosanelli C; Di Renzo N; Musso M; Pavone E; Santini G; Pescarollo A; De Crescenzo A; Federico M; Gallamini A; Pregno P; Romano R; Coser P; Gallo E; Boccadoro M; Barbui T; Pileri A; Gianni AM; Levis A
Cancer; 2003 Jun; 97(11):2748-59. PubMed ID: 12767087
[TBL] [Abstract][Full Text] [Related]
19. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE
Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
